Gold vs US Dollar

Register to chat with like-minded investors on our interactive forums.

Get Started

Valneva (VLA)

Valneva SE

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:EU:VLA

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
18/09/2024	06:00	GlobeNewswire Inc.	Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada	EU:VLA	Valneva SE
13/09/2024	07:30	GlobeNewswire Inc.	Valneva Announces the Success of its Private Placement Raising approximately €60 Million	EU:VLA	Valneva SE
03/09/2024	06:00	GlobeNewswire Inc.	Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate	EU:VLA	Valneva SE
13/08/2024	06:00	GlobeNewswire Inc.	Valneva Reports Half Year 2024 Financial Results and Provides Corporate Updates	EU:VLA	Valneva SE
01/08/2024	06:00	GlobeNewswire Inc.	Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate	EU:VLA	Valneva SE
22/07/2024	06:00	GlobeNewswire Inc.	CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine	EU:VLA	Valneva SE
17/07/2024	21:00	GlobeNewswire Inc.	Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion	EU:VLA	Valneva SE
04/07/2024	17:00	GlobeNewswire Inc.	Déclaration d’actions et de droits de vote - Valneva SE - 30 juin 2024	EU:VLA	Valneva SE
04/07/2024	17:00	GlobeNewswire Inc.	Declaration of shares and voting rights - Valneva SE - June 30, 2024	EU:VLA	Valneva SE
01/07/2024	06:00	GlobeNewswire Inc.	Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®	EU:VLA	Valneva SE
01/07/2024	06:00	GlobeNewswire Inc.	Valneva reçoit une autorisation de mise sur le marché en Europe pour le premier vaccin au monde contre le chikungunya, IXCHIQ®	EU:VLA	Valneva SE
01/07/2024	06:00	GlobeNewswire Inc.	Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ®	EU:VLA	Valneva SE
26/06/2024	16:45	GlobeNewswire Inc.	Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board	EU:VLA	Valneva SE
26/06/2024	16:45	GlobeNewswire Inc.	Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board	EU:VLA	Valneva SE
26/06/2024	16:45	GlobeNewswire Inc.	Valneva annonce l’approbation des résolutions présentées à son Assemblée Générale et la nomination d’un nouvel administrateur à son conseil d’administration	EU:VLA	Valneva SE
24/06/2024	06:00	GlobeNewswire Inc.	Valneva annonce l’approbation par Santé Canada du premier vaccin au monde contre le chikungunya, IXCHIQ®	EU:VLA	Valneva SE
24/06/2024	06:00	GlobeNewswire Inc.	Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®	EU:VLA	Valneva SE
24/06/2024	06:00	GlobeNewswire Inc.	Valneva Announces Health Canada Approval of the World’s First Chikungunya Vaccine, IXCHIQ®	EU:VLA	Valneva SE
05/06/2024	06:00	GlobeNewswire Inc.	Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update	EU:VLA	Valneva SE
05/06/2024	06:00	GlobeNewswire Inc.	Valneva annonce la mise à disposition des documents préparatoires à son Assemblée Générale Mixte et une évolution de son équipe de direction	EU:VLA	Valneva SE
05/06/2024	06:00	GlobeNewswire Inc.	Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update	EU:VLA	Valneva SE
04/06/2024	17:00	GlobeNewswire Inc.	VALNEVA - Declaration of shares and voting rights: May 31, 2024	EU:VLA	Valneva SE
04/06/2024	17:00	GlobeNewswire Inc.	VALNEVA - Déclaration d’actions et de droits de vote : 31 mai 2024	EU:VLA	Valneva SE
04/06/2024	16:35	GlobeNewswire Inc.	Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June	EU:VLA	Valneva SE
04/06/2024	16:35	GlobeNewswire Inc.	Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June	EU:VLA	Valneva SE
04/06/2024	16:35	GlobeNewswire Inc.	Valneva annonce sa participation à différentes conférences investisseurs du mois de juin	EU:VLA	Valneva SE
03/06/2024	16:35	GlobeNewswire Inc.	Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases	EU:VLA	Valneva SE
03/06/2024	16:35	GlobeNewswire Inc.	Valneva annonce la publication de deux essais de Phase 2 sur la maladie de Lyme dans le Lancet Infectious Diseases	EU:VLA	Valneva SE
03/06/2024	16:35	GlobeNewswire Inc.	Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases	EU:VLA	Valneva SE
31/05/2024	16:35	GlobeNewswire Inc.	Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine	EU:VLA	Valneva SE

Showing the most relevant articles for your search:EU:VLA

1 2 3 4 5 6 7 8 9 10 Next >>

Citi Holding 44

Wildcat Petroleum

Octopus Network Token

European Investment Bank

Pharmaceutical Select Po...

Banc of California

Barclays Bank Plc Autoca...

ACCENTRO Real Estate

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions